A. Keith Stewart, MB, ChB, and a panel of hematology experts review data concerning emerging frontline strategies for multiple myeloma that were presented at the 2017 ASH Annual Meeting.
In updated guidelines exploring the role of bone-modifying agents, ASCO has recommended expanding the use of bisphosphonates to include all patients being treated for active multiple myeloma.
Jeffrey Wolf, MD, emphasizes the importance of identifying risk when diagnosing patients with multiple myeloma.
Peter Voorhees, MD, discusses treatments for patients with early relapsed multiple myeloma and previews future research efforts.
The FDA has approved daratumumab in combination with bortezomib, melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
Saad Z. Usmani, MD, discusses the clinical applications of minimal residual disease and managing patients with relapsed/refractory multiple myeloma.
Selinexor induced an overall response rate of 25.4% in patients with penta-refractory multiple myeloma, according to top-line results from part 2 of the phase IIb STORM trial.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended adding final overall survival data from the phase III ASPIRE trial to the label for carfilzomib for the treatment of patients with relapsed/refractory multiple myeloma.
Keith Stewart, MB, ChB, discusses the role of stem cell transplant, minimal residual disease testing, and maintenance therapy in the treatment of patients with multiple myeloma.
Nitya Nathwani, MD, highlights current treatment options for transplant-ineligible multiple myeloma, as well as combinations on the horizon.